Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Reconstitute at 0.2 mg/mL in sterile PBS.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for IL-1 RAcP/IL-1 R3 Antibody [Unconjugated]
C3orf13IL-1RAcPIL1R3Interleukin-1 receptor 3
IL-1 receptor accessory protein
interleukin 1 receptor accessory protein
interleukin-1 receptor accessory protein beta
interleukin-1 receptor accessory protein
IL-1 Receptor Accessory Protein (also IL-1 R3) is a ubiquitous, 70-90 kDa member of the interleukin-1 receptor family of proteins (1-5). It serves as a non‑ligand‑binding accessory component of the receptors for IL-1 alpha, IL-1 beta, and IL-33 (6, 7). Together with IRAK4 and MyD88, it generates a functional signaling complex with IL‑1 RI; by itself, it generates a non-signaling, but high-affinity binding complex with IL-1 RII (8). In addition, it interacts with ST2 on mast cells and Th2 T cells to create a functional IL-33 receptor complex (7). Mature human IL-1 RAcP is a type I transmembrane glycoprotein that is 550 amino acids in length. It contains a 347 amino acid (aa) extracellular region (aa 21-367), a 21 aa transmembrane segment, and a 182 aa cytoplasmic domain (9). The extracellular region shows three C2‑type Ig-like domains, the most membrane proximal of which is suggested to be responsible for dimerization with IL-1 RI (10). There are three alternative splice forms reported for IL-1 RAcP. One is transmembrane, and shows a 239 aa substitution for the C-terminal 122 amino acids (11). The other two are soluble; one shows a six aa substitution for aa 351-570, while a second shows a 45 aa substitution for aa 302-579 (12, 13). The soluble receptor isoforms appear to be inhibitory to IL-1 signaling. When present with soluble IL-1 RII, soluble IL-1 RAcP increases the IL-1 binding affinity of IL-1 RII more than 100-fold, thus neutralizing the effects of IL-1 (14). The human and mouse IL-1 RAcP precursors are 89% aa identical; within the extracellular region, they share 86% aa identity.
Subramaniam, S. et al. (2004) Dev. Comp. Immunol. 28:415.
Boraschi, D. and A. Tagliabue (2006) Vitam. Horm. 74:229.
Dunne, A. and L.A.J. O'Neill (2003) Sci STKE. Feb 25;2003(171):re3.
Huang, J. et al. (1997) Proc. Natl. Acad. Sci. USA 94:12829.
Greenfeder, S. A. et al. (1995) J. Biol. Chem. 270:13757.
Brikos, C. et al. (2007) Mol. Cell. Proteomics 6:1551.
Chackerian, A.A. et al. (2007) J. Immunol. 179:2551.
Lang, D. et al. (1998) J. Immunol. 161:6871.
SwissProt. Accession # Q9NPH3.
Yoon, D-Y. and C.A. Dinarello (1998) J. Immunol. 160:3170.
Lu, H-L. et al. (2008) Mol. Immunol. 45:1374.
Jensen, L.E. et al. (2000) J. Immunol. 164:5277.
Jensen, L.E. and A.S. Whitehead (2003) Cell. Signal. 15:793.
Smith, D.E. et al. (2003) Immunity 18:87.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our IL-1 RAcP/IL-1 R3 Antibody [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.